share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外國發行人報告（業績相關）
美股sec公告 ·  05/24 17:08
Moomoo AI 已提取核心訊息
Apollomics Inc., a biopharmaceutical company, has established an 'At the Market' sales program, entering into a Sales Agreement with Cantor Fitzgerald & Co. on May 24, 2024. The agreement allows for the sale of up to $19 million of the company's Class A ordinary shares. The sales will be conducted as needed in the market, without any obligation for the company to sell a specific number of shares. The Sales Agent will receive a 3.0% commission on the gross proceeds from the sales. Both Apollomics and the Sales Agent have the right to terminate the agreement under certain conditions, including a significant adverse change in Apollomics' business or financial condition. The offering will conclude once the total sales reach $19 million or if the Sales Agreement is terminated. This move is part of Apollomics' efforts to raise capital through its effective registration statement on Form F-3.
Apollomics Inc., a biopharmaceutical company, has established an 'At the Market' sales program, entering into a Sales Agreement with Cantor Fitzgerald & Co. on May 24, 2024. The agreement allows for the sale of up to $19 million of the company's Class A ordinary shares. The sales will be conducted as needed in the market, without any obligation for the company to sell a specific number of shares. The Sales Agent will receive a 3.0% commission on the gross proceeds from the sales. Both Apollomics and the Sales Agent have the right to terminate the agreement under certain conditions, including a significant adverse change in Apollomics' business or financial condition. The offering will conclude once the total sales reach $19 million or if the Sales Agreement is terminated. This move is part of Apollomics' efforts to raise capital through its effective registration statement on Form F-3.
生物製藥公司Apollomics Inc. 已經制定了 “在市場上” 的銷售計劃，並於2024年5月24日與坎託·菲茨傑拉德公司簽訂了銷售協議。該協議允許出售該公司高達1900萬美元的A類普通股。銷售將根據市場需要進行，公司沒有任何義務出售特定數量的股票。銷售代理將從銷售總收益中獲得3.0％的佣金。Apollomics和銷售代理都有權在某些條件下終止協議，包括Apollomics的業務或財務狀況發生重大不利變化。一旦總銷售額達到1900萬美元或銷售協議終止，此次發行將結束。此舉是Apollomics通過其在F-3表格上的有效註冊聲明籌集資金的努力的一部分。
生物製藥公司Apollomics Inc. 已經制定了 “在市場上” 的銷售計劃，並於2024年5月24日與坎託·菲茨傑拉德公司簽訂了銷售協議。該協議允許出售該公司高達1900萬美元的A類普通股。銷售將根據市場需要進行，公司沒有任何義務出售特定數量的股票。銷售代理將從銷售總收益中獲得3.0％的佣金。Apollomics和銷售代理都有權在某些條件下終止協議，包括Apollomics的業務或財務狀況發生重大不利變化。一旦總銷售額達到1900萬美元或銷售協議終止，此次發行將結束。此舉是Apollomics通過其在F-3表格上的有效註冊聲明籌集資金的努力的一部分。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息